Kyverna reports positive Phase 2 interim data for KYV-101 in gMG; 100% response rate

Kyverna Therapeutics, Inc.

100% (6/6) of patients achieved clinically meaningful reductions in MG-ADL and QMG at 24 weeks.
Mean reductions of -8.0 points (MG-ADL) and -7.7 points (QMG) from baseline; responses seen as early as 2 weeks.
No high-grade CRS or ICANS observed; one SAE of Grade 4 neutropenia resolved to Grade 1.
All patients free of nonsteroidal immunosuppressants, high-dose steroids, FcRn, and complement inhibitors.
Company plans to initiate Phase 3 portion of KYSA-6 trial by end of 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.